Peter McWilliams is a Managing Director with Sanderling Ventures and has more than 15 years experience in biomedical research and management. He works actively with Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. Portfolio companies include Actimis Pharmaceuticals (sold to Boehringer Ingelheim), Artielle Immunotherapeutics, Harkness Pharmaceuticals, Calcimedica and Cylene Pharmaceuticals.Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin. Prior to that he was an Associate with Booz.Allen & Hamilton in San Francisco where he focused on projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics, where he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange.
Peter McWilliams's details
- Country: United States
- Region: San Mateo, California
- Studies: Managing Director
- University: Sanderling Ventures
- Peter McWilliams's presentations
Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.
This post is also available in: French